All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, April 1, 2023
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

US enforcement for medical testing to remain dangerously robust in 2023

Dec. 20, 2022
By Mark McCarty
No Comments
U.S. federal authorities have made a lot of noise over inappropriate medical testing in the past two years, largely due to the COVID-19 pandemic, but Paul Garcia, a partner in the San Diego office of Hooper, Lundy & Bookman PC, says this trend will not ebb at all in the coming year. Garcia told BioWorld that the lookback period for Medicare testing claims runs several years and that not only will enforcement results continue to surface next year, but also that the associated civil monetary penalties could force a testing lab to shutter its operations permanently.
Read More

Other news to note for Dec. 20, 2022

Dec. 20, 2022
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amgen, Angiocrine, Arrowhead, Carrick, Catalyst, Eisai, Menarini, Merck, Paratek, Pfizer, Royalty.
Read More

Regulatory actions for Dec. 19, 2022

Dec. 19, 2022
No Comments
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Alexbio, Amicus, Apellis, Boehringer Ingelheim, CSL Behring, Eli Lilly, Jacobio, Miromatrix, Moderna, Ocugen, Roche, Regeneron, Sanofi, Uniqure, Y-Mabs.
Read More

In the clinic for Dec. 19, 2022

Dec. 19, 2022
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aelis, Astellas, Bioved, Cerevel, Equillium, Krystal, Mimivax, Ocugen, Palisade, Skye, Synaptogenix.
Read More
Scientist with vial
Immune

Biovaxys reports outcomes from pan-sarbecovirus vaccine animal study

Dec. 19, 2022
No Comments
Biovaxys Technology Corp. has announced...
Read More
SARS-CoV-2 illustration turns from blue to red

WTO divided over expanding COVID-19 IP waiver

Dec. 16, 2022
By Mari Serebrov
No Comments
One of the big regulatory and pandemic stories of 2022 with global impact was the June 17 World Trade Organization’s (WTO) agreement on a five-year intellectual property (IP) waiver for COVID-19 vaccines and their components.
Read More

Other news to note for Dec. 15, 2022

Dec. 15, 2022
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Abcellera, Apotex, Atyr, Axcella, Biocryst, Gri, Immix, Kaleibe, Nexcella, Nimble, Oxford Biomedica, Phoremost, Poolbeg, Praxis, Psyence, Qrons, Qu, Replay, Selecta, Sio, Sumitomo, Teva, Thinkcyte, UCB, Urica, Valbiotis, Vallon, Vanda, Woodward.
Read More

In the clinic for Dec. 15, 2022

Dec. 15, 2022
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actinogen, Alto, Avidity, Catalym, Dermaliq, Ellipses, Epicentrx, Imaginab, Geneos, Genprex, Icosavax, Irlab, Kymera, Moonlake, Oxurion, Passage, Precision, Quoin, Recbio, Splisense, Tracon, Ultimovacs.
Read More

Other news to note for Dec. 15, 2022

Dec. 15, 2022
No Comments
Additional early-stage research and drug discovery news in brief, from: Dyadic, Nuvalent.
Read More
Colorized transmission electron micrograph of rabies virus.
Infection

Everest achieves preclinical proof-of-concept milestone for its mRNA rabies vaccine

Dec. 15, 2022
No Comments
Everest Medicines Ltd. has achieved a preclinical proof-of-concept milestone for its mRNA rabies vaccine program. This new vaccine candidate for rabies post-exposure prophylaxis was developed in partnership with Providence Therapeutics Holdings Inc. utilizing a clinically validated mRNA technology platform.
Read More
Previous 1 2 … 12 13 14 15 16 17 18 19 20 … 503 504 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 31, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 31, 2023.
  • Mbiomics raises €13M to pivot to microbiome-based therapeutic development

    BioWorld
    Mbiomics GmbH raised €13 million (US$14.2 million) in a first close of a series A round that will enable it to pivot from being a microbiome analytics firm to...
  • Bio-Europe Spring 2023: Despite funding woes, biotechs weather the storm with deals

    BioWorld
    Are deals such as M&As between biotechs and big pharma becoming a thing of the past? That was a key question posed during the opening keynote at this year’s...
  • Biohaven acquires early stage TYK2/JAK1 inhibitor from Highlightll in $970M deal

    BioWorld
    Biohaven Ltd. has acquired global rights, excluding China, from Highlightll Pharmaceutical Co. Ltd. to develop and commercialize a dual inhibitor of tyrosine...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing